|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: YWHAG |
Gene summary for YWHAG |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | YWHAG | Gene ID | 7532 |
| Gene name | tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma | |
| Gene Alias | 14-3-3GAMMA | |
| Cytomap | 7q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0001932 | UniProtAcc | P61981 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7532 | YWHAG | LZE4T | Human | Esophagus | ESCC | 6.84e-03 | 5.28e-01 | 0.0811 |
| 7532 | YWHAG | LZE8T | Human | Esophagus | ESCC | 1.61e-08 | 9.01e-02 | 0.067 |
| 7532 | YWHAG | LZE20T | Human | Esophagus | ESCC | 7.76e-14 | -1.15e-02 | 0.0662 |
| 7532 | YWHAG | LZE24T | Human | Esophagus | ESCC | 1.99e-03 | 5.73e-01 | 0.0596 |
| 7532 | YWHAG | P2T-E | Human | Esophagus | ESCC | 1.53e-12 | 2.96e-01 | 0.1177 |
| 7532 | YWHAG | P4T-E | Human | Esophagus | ESCC | 8.56e-18 | 8.05e-01 | 0.1323 |
| 7532 | YWHAG | P5T-E | Human | Esophagus | ESCC | 3.55e-17 | 6.42e-01 | 0.1327 |
| 7532 | YWHAG | P8T-E | Human | Esophagus | ESCC | 2.49e-04 | 6.03e-03 | 0.0889 |
| 7532 | YWHAG | P9T-E | Human | Esophagus | ESCC | 2.45e-14 | 4.22e-01 | 0.1131 |
| 7532 | YWHAG | P10T-E | Human | Esophagus | ESCC | 3.15e-17 | 6.41e-01 | 0.116 |
| 7532 | YWHAG | P11T-E | Human | Esophagus | ESCC | 1.70e-07 | 1.04e+00 | 0.1426 |
| 7532 | YWHAG | P12T-E | Human | Esophagus | ESCC | 2.10e-32 | 1.11e+00 | 0.1122 |
| 7532 | YWHAG | P15T-E | Human | Esophagus | ESCC | 1.20e-18 | 9.37e-01 | 0.1149 |
| 7532 | YWHAG | P16T-E | Human | Esophagus | ESCC | 7.48e-43 | 1.71e+00 | 0.1153 |
| 7532 | YWHAG | P19T-E | Human | Esophagus | ESCC | 7.87e-05 | 1.17e+00 | 0.1662 |
| 7532 | YWHAG | P20T-E | Human | Esophagus | ESCC | 3.67e-12 | 8.10e-01 | 0.1124 |
| 7532 | YWHAG | P21T-E | Human | Esophagus | ESCC | 8.93e-23 | 1.03e+00 | 0.1617 |
| 7532 | YWHAG | P22T-E | Human | Esophagus | ESCC | 3.39e-13 | 4.94e-01 | 0.1236 |
| 7532 | YWHAG | P23T-E | Human | Esophagus | ESCC | 3.62e-11 | 6.94e-01 | 0.108 |
| 7532 | YWHAG | P24T-E | Human | Esophagus | ESCC | 5.71e-07 | 5.33e-01 | 0.1287 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
| GO:0010563111 | Esophagus | ESCC | negative regulation of phosphorus metabolic process | 274/8552 | 442/18723 | 2.32e-12 | 9.41e-11 | 274 |
| GO:0045936111 | Esophagus | ESCC | negative regulation of phosphate metabolic process | 273/8552 | 441/18723 | 3.18e-12 | 1.25e-10 | 273 |
| GO:0051348111 | Esophagus | ESCC | negative regulation of transferase activity | 177/8552 | 268/18723 | 1.08e-11 | 4.00e-10 | 177 |
| GO:0042326111 | Esophagus | ESCC | negative regulation of phosphorylation | 237/8552 | 385/18723 | 1.86e-10 | 5.33e-09 | 237 |
| GO:0001933111 | Esophagus | ESCC | negative regulation of protein phosphorylation | 213/8552 | 342/18723 | 3.54e-10 | 9.76e-09 | 213 |
| GO:003367319 | Esophagus | ESCC | negative regulation of kinase activity | 154/8552 | 237/18723 | 1.38e-09 | 3.27e-08 | 154 |
| GO:000646920 | Esophagus | ESCC | negative regulation of protein kinase activity | 140/8552 | 212/18723 | 1.53e-09 | 3.56e-08 | 140 |
| GO:190165319 | Esophagus | ESCC | cellular response to peptide | 208/8552 | 359/18723 | 1.68e-06 | 2.01e-05 | 208 |
| GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
| GO:003286918 | Esophagus | ESCC | cellular response to insulin stimulus | 124/8552 | 203/18723 | 6.63e-06 | 6.75e-05 | 124 |
| GO:003286818 | Esophagus | ESCC | response to insulin | 156/8552 | 264/18723 | 7.21e-06 | 7.20e-05 | 156 |
| GO:007137516 | Esophagus | ESCC | cellular response to peptide hormone stimulus | 166/8552 | 290/18723 | 4.48e-05 | 3.55e-04 | 166 |
| GO:00066057 | Liver | Cirrhotic | protein targeting | 148/4634 | 314/18723 | 3.86e-18 | 6.20e-16 | 148 |
| GO:004343412 | Liver | Cirrhotic | response to peptide hormone | 149/4634 | 414/18723 | 1.70e-07 | 4.49e-06 | 149 |
| GO:007137511 | Liver | Cirrhotic | cellular response to peptide hormone stimulus | 110/4634 | 290/18723 | 3.73e-07 | 8.82e-06 | 110 |
| GO:004593612 | Liver | Cirrhotic | negative regulation of phosphate metabolic process | 154/4634 | 441/18723 | 8.78e-07 | 1.83e-05 | 154 |
| GO:001056312 | Liver | Cirrhotic | negative regulation of phosphorus metabolic process | 154/4634 | 442/18723 | 1.02e-06 | 2.11e-05 | 154 |
| GO:190165311 | Liver | Cirrhotic | cellular response to peptide | 129/4634 | 359/18723 | 1.23e-06 | 2.49e-05 | 129 |
| GO:003286911 | Liver | Cirrhotic | cellular response to insulin stimulus | 80/4634 | 203/18723 | 2.55e-06 | 4.63e-05 | 80 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
| hsa051609 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
| hsa041517 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa041146 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
| hsa0516016 | Esophagus | ESCC | Hepatitis C | 107/4205 | 157/8465 | 1.75e-06 | 1.08e-05 | 5.55e-06 | 107 |
| hsa0415114 | Esophagus | ESCC | PI3K-Akt signaling pathway | 197/4205 | 354/8465 | 1.24e-02 | 2.83e-02 | 1.45e-02 | 197 |
| hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0411411 | Esophagus | ESCC | Oocyte meiosis | 77/4205 | 131/8465 | 2.19e-02 | 4.80e-02 | 2.46e-02 | 77 |
| hsa051605 | Liver | Cirrhotic | Hepatitis C | 63/2530 | 157/8465 | 3.67e-03 | 1.49e-02 | 9.20e-03 | 63 |
| hsa041104 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa05203 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 |
| hsa0516012 | Liver | Cirrhotic | Hepatitis C | 63/2530 | 157/8465 | 3.67e-03 | 1.49e-02 | 9.20e-03 | 63 |
| hsa0411011 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
| hsa052031 | Liver | Cirrhotic | Viral carcinogenesis | 76/2530 | 204/8465 | 1.34e-02 | 4.20e-02 | 2.59e-02 | 76 |
| hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
| hsa0516021 | Liver | HCC | Hepatitis C | 94/4020 | 157/8465 | 1.11e-03 | 4.10e-03 | 2.28e-03 | 94 |
| Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| YWHAG | SNV | Missense_Mutation | novel | c.268G>C | p.Glu90Gln | p.E90Q | P61981 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.957) | TCGA-E2-A14V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| YWHAG | SNV | Missense_Mutation | c.137N>G | p.Ser46Cys | p.S46C | P61981 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-E9-A1N4-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| YWHAG | insertion | In_Frame_Ins | novel | c.598_599insAAAACTTAAAGAGGAATGGCCCTCATTCAGTAAGTT | p.Ala200delinsGluAsnLeuLysArgAsnGlyProHisSerValSerSer | p.A200delinsENLKRNGPHSVSS | P61981 | protein_coding | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| YWHAG | SNV | Missense_Mutation | c.212N>A | p.Ser71Tyr | p.S71Y | P61981 | protein_coding | deleterious_low_confidence(0) | benign(0.188) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| YWHAG | SNV | Missense_Mutation | c.330N>T | p.Lys110Asn | p.K110N | P61981 | protein_coding | deleterious_low_confidence(0.01) | benign(0.043) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| YWHAG | SNV | Missense_Mutation | novel | c.700N>G | p.Thr234Ala | p.T234A | P61981 | protein_coding | deleterious_low_confidence(0.03) | probably_damaging(0.975) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| YWHAG | SNV | Missense_Mutation | novel | c.220N>A | p.Gly74Ser | p.G74S | P61981 | protein_coding | tolerated_low_confidence(0.07) | probably_damaging(0.999) | TCGA-AJ-A3OK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| YWHAG | SNV | Missense_Mutation | novel | c.481N>G | p.Ser161Gly | p.S161G | P61981 | protein_coding | deleterious_low_confidence(0.02) | probably_damaging(0.991) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| YWHAG | SNV | Missense_Mutation | novel | c.489N>T | p.Glu163Asp | p.E163D | P61981 | protein_coding | tolerated_low_confidence(0.29) | benign(0.114) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| YWHAG | SNV | Missense_Mutation | c.340G>A | p.Glu114Lys | p.E114K | P61981 | protein_coding | tolerated_low_confidence(0.28) | benign(0.001) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7532 | YWHAG | DRUGGABLE GENOME, KINASE | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | ||
| 7532 | YWHAG | DRUGGABLE GENOME, KINASE | DOXORUBICIN HYDROCHLORIDE | DOXORUBICIN HYDROCHLORIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |